-
2
-
-
84864856267
-
-
Ottawa: Bank of Canada; Available from: Accessed 19 March 2014
-
Bank of Canada inflation calculator. Ottawa: Bank of Canada; 2012. Available from: http://www.bankofcanada.ca/rates/related/inflation-calculator/. Accessed 19 March 2014.
-
(2012)
Bank of Canada Inflation Calculator
-
-
-
3
-
-
22944483754
-
Incorporating economic evaluations into decisionmaking: The Ontario experience
-
Laupacis A. Incorporating economic evaluations into decisionmaking: the Ontario experience. Med Care. 2005;43(7, Suppl): 15-9.
-
(2005)
Med Care
, vol.43
, Issue.7
, pp. 15-19
-
-
Laupacis, A.1
-
4
-
-
31544452135
-
Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy
-
Clarke JT. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ. 2006;174(2):189-90.
-
(2006)
CMAJ
, vol.174
, Issue.2
, pp. 189-190
-
-
Clarke, J.T.1
-
5
-
-
74549137967
-
-
Toronto: Canadian Organization for Rare Disorders; Available from: Accessed 19 March 2014
-
Canadian Organization for Rare Disorders. Canada's Orphan Drug Policy: Learning from the Best. Toronto: Canadian Organization for Rare Disorders; 2005. Available from: http://www.raredisorders.ca/documents/CanadaOrphanDPFinal.pdf. Accessed 19 March 2014.
-
(2005)
Canada's Orphan Drug Policy: Learning from the Best
-
-
-
6
-
-
27644486590
-
Orphan drugs and the NHS: Should we value rarity?
-
McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? Br Med J. 2005;331:1016-19.
-
(2005)
Br Med J
, vol.331
, pp. 1016-1019
-
-
McCabe, C.1
Claxton, K.2
Tsuchiya, A.3
-
7
-
-
78649652812
-
Policy alternatives for treatments for rare diseases
-
Panju AH, Bell CM. Policy alternatives for treatments for rare diseases. CMAJ. 2010;182(17):E787-92.
-
(2010)
CMAJ
, vol.182
, Issue.17
, pp. E787-E792
-
-
Panju, A.H.1
Bell, C.M.2
-
8
-
-
84866354190
-
An evaluation framework for funding drugs for rare disease
-
Winquist E, Bell CM, Clarke JTR, et al. An evaluation framework for funding drugs for rare disease. Value Health. 2012;15:982-6.
-
(2012)
Value Health
, vol.15
, pp. 982-986
-
-
Winquist, E.1
Bell, C.M.2
Clarke, J.T.R.3
-
9
-
-
0028802443
-
Natural history of paroxysmal nocturnal hemoglobinuria
-
?Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-8.
-
(1995)
N Engl J Med
, vol.333
, pp. 1253-1258
-
-
Hillmen, P.1
Lewis, S.M.2
Bessler, M.3
Luzzatto, L.4
Dacie, J.V.5
-
10
-
-
77955318428
-
?The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire
-
Hill A, Platts PJ, Smith A, et al. ?The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract 0067]. Haematologica. 2007;92(Suppl 2):25.
-
(2007)
Haematologica
, vol.92
, pp. 25
-
-
Hill, A.1
Platts, P.J.2
Smith, A.3
-
11
-
-
34047221441
-
Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria
-
Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137(3):181-92.
-
(2007)
Br J Haematol
, vol.137
, Issue.3
, pp. 181-192
-
-
Hill, A.1
Richards, S.J.2
Hillmen, P.3
-
12
-
-
16044365965
-
Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors
-
French Society of Haematology
-
Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573-7.
-
(1996)
Lancet
, vol.348
, Issue.9027
, pp. 573-577
-
-
Socié, G.1
Mary, J.Y.2
De Gramont, A.3
-
13
-
-
35948962168
-
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
-
Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123-8.
-
(2007)
Blood
, vol.110
, pp. 4123-4128
-
-
Hillmen, P.1
Muus, P.2
Dührsen, U.3
-
14
-
-
33748904355
-
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
-
Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-43.
-
(2006)
N Engl J Med
, vol.355
, Issue.12
, pp. 1233-1243
-
-
Hillmen, P.1
Young, N.S.2
Schubert, J.3
-
15
-
-
77955486794
-
Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria
-
Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010; 85(8):553-9.
-
(2010)
Am J Hematol
, vol.85
, Issue.8
, pp. 553-559
-
-
Hillmen, P.1
Elebute, M.2
Kelly, R.3
-
16
-
-
79958849218
-
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival
-
Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786-92.
-
(2011)
Blood
, vol.117
, Issue.25
, pp. 6786-6792
-
-
Kelly, R.J.1
Hill, A.2
Arnold, L.M.3
-
18
-
-
0031886073
-
An introduction to Markov modelling for economic evaluation
-
Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409.
-
(1998)
Pharmacoeconomics
, vol.13
, Issue.4
, pp. 397-409
-
-
Briggs, A.1
Sculpher, M.2
-
19
-
-
0242494954
-
Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)
-
Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102(10):3587-91.
-
(2003)
Blood
, vol.102
, Issue.10
, pp. 3587-3591
-
-
Hall, C.1
Richards, S.2
Hillmen, P.3
-
20
-
-
34247614032
-
Thrombosis in paroxysmal nocturnal hemoglobinuria: Sites, risks, outcome. An overview
-
Ziakas P, Poulou L, Rokas K, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007;5:642-5.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 642-645
-
-
Ziakas, P.1
Poulou, L.2
Rokas, K.3
Bartzoudis, D.4
Voulgarelis, M.5
-
21
-
-
62849104641
-
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
-
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
-
(2009)
Lancet Oncol
, vol.10
, Issue.3
, pp. 223-232
-
-
Fenaux, P.1
Mufti, G.J.2
Hellstrom-Lindberg, E.3
-
23
-
-
34548384965
-
Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: A Canadian perspective
-
Coyle D, Rodby R, Soroka S, et al. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. Clin Ther. 2007;29:1508-23.
-
(2007)
Clin Ther
, vol.29
, pp. 1508-1523
-
-
Coyle, D.1
Rodby, R.2
Soroka, S.3
-
24
-
-
77956712811
-
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusiondependent myelodysplastic syndrome patients
-
Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusiondependent myelodysplastic syndrome patients. J Med Econ. 2010;13(3):559-70.
-
(2010)
J Med Econ
, vol.13
, Issue.3
, pp. 559-570
-
-
Tolley, K.1
Oliver, N.2
Miranda, E.3
Migliaccio-Walle, K.4
Bozkaya, D.5
Li, Q.6
-
25
-
-
34247271478
-
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusiondependent thalassaemia patients: US healthcare system perspective
-
Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusiondependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25:329-42.
-
(2007)
Pharmacoeconomics
, vol.25
, pp. 329-342
-
-
Delea, T.E.1
Sofrygin, O.2
Thomas, S.K.3
Baladi, J.F.4
Phatak, P.D.5
Coates, T.D.6
-
26
-
-
0028805628
-
Sporadic meningococcal disease in adults: Results of a 5-year population-based study
-
Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med. 1995;123(12):937-40.
-
(1995)
Ann Intern Med
, vol.123
, Issue.12
, pp. 937-940
-
-
Stephens, D.S.1
Hajjeh, R.A.2
Baughman, W.S.3
Harvey, R.C.4
Wenger, J.D.5
Farley, M.M.6
-
27
-
-
7944231114
-
The incidence and mortality for meningococcal disease associated with area deprivation: An ecological study of hospital episode statistics
-
Heyderman RS, Ben-Shlomo Y, Brennan CA, Somerset M. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child. 2004;89(11):1064-8.
-
(2004)
Arch Dis Child
, vol.89
, Issue.11
, pp. 1064-1068
-
-
Heyderman, R.S.1
Ben-Shlomo, Y.2
Brennan, C.A.3
Somerset, M.4
-
29
-
-
0028296769
-
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
-
Levine M, Hirsh J, Gent M. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343(8902):886-9.
-
(1994)
Lancet
, vol.343
, Issue.8902
, pp. 886-889
-
-
Levine, M.1
Hirsh, J.2
Gent, M.3
-
30
-
-
0037431013
-
Long-term, lowintensity warfarin therapy for the prevention of recurrent venous thromboembolism
-
Ridker PM, Goldhaber SZ, Danielson E. Long-term, lowintensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425-34.
-
(2003)
N Engl J Med
, vol.348
, Issue.15
, pp. 1425-1434
-
-
Ridker, P.M.1
Goldhaber, S.Z.2
Danielson, E.3
-
31
-
-
71049152788
-
Valuation of transfusion-free living in MDS: Results of health utility interviews with patients
-
Szende A, Schaefer C, Goss TF, Heptinstall K, Knight R, Lübbert M. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7:81.
-
(2009)
Health Qual Life Outcomes
, vol.7
, pp. 81
-
-
Szende, A.1
Schaefer, C.2
Goss, T.F.3
Heptinstall, K.4
Knight, R.5
Lübbert, M.6
-
32
-
-
85044709641
-
Hormonal therapies for early breast cancer: Systematic review and economic evaluation
-
Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26):iii-iv, ix-xi, 1-134.
-
(2007)
Health Technol Assess
, vol.11
, Issue.26
-
-
Hind, D.1
Ward, S.2
De Nigris, E.3
Simpson, E.4
Carroll, C.5
Wyld, L.6
-
33
-
-
32844464374
-
Health-related quality of life and estimates of utility in chronic kidney disease
-
Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801-8.
-
(2005)
Kidney Int
, vol.68
, pp. 2801-2808
-
-
Gorodetskaya, I.1
Zenios, S.2
McCulloch, C.E.3
-
34
-
-
0032925807
-
Low-molecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A cost-effectiveness analysis
-
Gould MK, Dembitzer AD, Sanders GD, Garner AM. Low-molecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med. 1999;130:789-99.
-
(1999)
Ann Intern Med
, vol.130
, pp. 789-799
-
-
Gould, M.K.1
Dembitzer, A.D.2
Sanders, G.D.3
Garner, A.M.4
-
35
-
-
82955169580
-
The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer
-
Younis T, Rayson D, Skedgel C. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol. 2011;18(6):e288-96.
-
(2011)
Curr Oncol
, vol.18
, Issue.6
, pp. e288-e296
-
-
Younis, T.1
Rayson, D.2
Skedgel, C.3
-
37
-
-
4844222413
-
The societal unit cost of allogenic red cells and red cell transfusion in Canada
-
Amin M, Fergusson D, Wilson K, et al. The societal unit cost of allogenic red cells and red cell transfusion in Canada. Transfusion. 2004;44:1479-86.
-
(2004)
Transfusion
, vol.44
, pp. 1479-1486
-
-
Amin, M.1
Fergusson, D.2
Wilson, K.3
-
38
-
-
33745662843
-
Costeffectiveness of self-managed versus physician-managed oral anticoagulation therapy
-
Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Costeffectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ. 2006;174(13):1847-52.
-
(2006)
CMAJ
, vol.174
, Issue.13
, pp. 1847-1852
-
-
Regier, D.A.1
Sunderji, R.2
Lynd, L.D.3
Gin, K.4
Marra, C.A.5
-
39
-
-
79955774273
-
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
-
Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908-19.
-
(2011)
Thromb Haemost
, vol.105
, pp. 908-919
-
-
Sorensen, S.V.1
Kansal, A.R.2
Connolly, S.3
-
40
-
-
82755195008
-
Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: A prospective evaluation
-
Guanella R, Ducruet T, Johri M, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost. 2011;9:2397-405.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 2397-2405
-
-
Guanella, R.1
Ducruet, T.2
Johri, M.3
-
41
-
-
78549238147
-
Cost of transfusiondependent myelodysplastic syndrome (MDS) from a German payer's perspective
-
Kühne F, Mittendorf T, Germing U. Cost of transfusiondependent myelodysplastic syndrome (MDS) from a German payer's perspective. Ann Hematol. 2010;89:1239-47.
-
(2010)
Ann Hematol
, vol.89
, pp. 1239-1247
-
-
Kühne, F.1
Mittendorf, T.2
Germing, U.3
-
42
-
-
0035081928
-
Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands
-
Uyl-De Groot CA, Gelderblom-Den Hartog J, Huijgens PC, Willemze R, Van Ineveld M. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hem Stem Cell Res. 2001;10:187-92.
-
(2001)
J Hem Stem Cell Res
, vol.10
, pp. 187-192
-
-
Uyl-De Groot, C.A.1
Gelderblom-Den Hartog, J.2
Huijgens, P.C.3
Willemze, R.4
Van Ineveld, M.5
-
43
-
-
78349232816
-
Population based screening for chronic kidney disease: Cost effectiveness study
-
Manns B, Hemmelgarn B, Tonelli M, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ. 2010;341:c5869.
-
(2010)
BMJ
, vol.341
, pp. c5869
-
-
Manns, B.1
Hemmelgarn, B.2
Tonelli, M.3
-
45
-
-
84879409410
-
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation
-
Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498-506.
-
(2013)
Value Health
, vol.16
, Issue.4
, pp. 498-506
-
-
Coyle, D.1
Coyle, K.2
Cameron, C.3
-
46
-
-
84909625921
-
Advice for consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine, for use by provinces and territories
-
Public Health Agency of Canada. Advice for consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine, for use by provinces and territories. Can Communicable Dis Rep (CCDR). 2010;36:S2.
-
(2010)
Can Communicable Dis Rep (CCDR)
, vol.36
, pp. S2
-
-
Public Health Agency of Canada1
-
47
-
-
84909599134
-
-
Victoria: British Columbia Ministry of Health; Available from: Accessed 19 March 2014
-
British Columbia Ministry of Health. Pharmacare Formulary. Victoria: British Columbia Ministry of Health; 2012. Available from: http://www.health.gov.bc.ca/pharmacare/benefitslookup/. Accessed 19 March 2014.
-
(2012)
Pharmacare Formulary
-
-
-
48
-
-
33846118263
-
Rates and probabilities in economic modelling: Transformation, translation and appropriate application
-
Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2007;25:3-6.
-
(2007)
Pharmacoeconomics
, vol.25
, pp. 3-6
-
-
Fleurence, R.L.1
Hollenbeak, C.S.2
-
50
-
-
0034086702
-
Handling uncertainty in cost-effectiveness models
-
Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500.
-
(2000)
Pharmacoeconomics
, vol.17
, pp. 479-500
-
-
Briggs, A.H.1
-
51
-
-
0026575912
-
How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations
-
Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-81.
-
(1992)
CMAJ
, vol.146
, pp. 473-481
-
-
Laupacis, A.1
Feeny, D.2
Detsky, A.S.3
Tugwell, P.X.4
-
52
-
-
84909646437
-
-
Toronto: Ontario Nurses Association; Available from: Accessed 19 March 2014
-
Ontario Nurses Association. Unions and the Ontario Nurses' Association 2012. Toronto: Ontario Nurses Association; 2012. Available from: http://www.ona.org/faqs.html. Accessed 19 March 2014.
-
(2012)
Unions and the Ontario Nurses' Association 2012
-
-
-
53
-
-
84909643222
-
-
Toronto, Canada: Ontario Ministry of Health and Long Term Care; Available from: Accessed 19 March 2014
-
Ontario Ministry of Health and Long Term Care. Ambulance Services Billing 2012. Toronto, Canada: Ontario Ministry of Health and Long Term Care; 2012. Available from: http://www.health.gov.on.ca/en/public/publications/ohip/amb.aspx. Accessed 19 March 2014.
-
(2012)
Ambulance Services Billing 2012
-
-
-
54
-
-
84909630326
-
-
Available from: Accessed 19 March 2014
-
Manulife Canada. Long Term Care in Ontario 2010. Available from: https://repsourcepublic.manulife.com/wps/wcm/connect/repsourceFormsMktg/MarketingMaterials/Insurance/LivingCare/ins-livcare-ontarioltccostreport?presentationtemplate=repsourceDesign/showPDF. Accessed 19 March 2014.
-
Long Term Care in Ontario 2010
-
-
-
55
-
-
84927572690
-
-
November Available from: Accessed 19 March 2014
-
Mood Disorders Society of Canada. Quick Facts on Mental Illness and Addictions in Canada, 3rd Edition (November 2009). Available from: http://www.mooddisorderscanada.ca/page/quick-facts. Accessed 19 March 2014.
-
(2009)
Quick Facts on Mental Illness and Addictions in Canada, 3rd Edition
-
-
-
56
-
-
84864198277
-
Orphan drugs for rare diseases: Is it time to revisit their special market access status?
-
Simoens S, Cassiman D, Dooms M, Picavet E. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72:1437-43.
-
(2012)
Drugs
, vol.72
, pp. 1437-1443
-
-
Simoens, S.1
Cassiman, D.2
Dooms, M.3
Picavet, E.4
-
57
-
-
0034822074
-
Managing public payment for high cost, high-benefit treatment: Enzyme replacement therapy for Gaucher's disease in Ontario
-
Clarke JTR, Amato D, Deber RB. Managing public payment for high cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. CMAJ. 2001;165:595-6.
-
(2001)
CMAJ
, vol.165
, pp. 595-596
-
-
Clarke, J.T.R.1
Amato, D.2
Deber, R.B.3
-
58
-
-
27744461277
-
Drugs for exceptionally rare diseases: Do they deserve special status for funding?
-
Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98(11):829-36.
-
(2005)
QJM
, vol.98
, Issue.11
, pp. 829-836
-
-
Hughes, D.A.1
Tunnage, B.2
Yeo, S.T.3
-
59
-
-
34247504244
-
Assessing the economic challenges posed by orphan drugs
-
Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36-42.
-
(2007)
Int J Technol Assess Health Care
, vol.23
, Issue.1
, pp. 36-42
-
-
Drummond, M.F.1
Wilson, D.A.2
Kanavos, P.3
Ubel, P.4
Rovira, J.5
-
61
-
-
84890848005
-
Can the NICE "end-of-life premium" be given a coherent ethical justification?
-
Cookson R. Can the NICE "end-of-life premium" be given a coherent ethical justification? J Health Polit Policy Law. 2013;38(6):1129-48.
-
(2013)
J Health Polit Policy Law
, vol.38
, Issue.6
, pp. 1129-1148
-
-
Cookson, R.1
-
63
-
-
84881344116
-
Prioritizing treatment of rare diseases: A survey of preferences of Norwegian doctors
-
Desser AS. Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors. Soc Sci Med. 2013;94:56-62.
-
(2013)
Soc Sci Med
, vol.94
, pp. 56-62
-
-
Desser, A.S.1
-
64
-
-
84900754530
-
Health charities get 'covert' aid from drug firms
-
December 3
-
Templeton S-K. Health charities get 'covert' aid from drug firms. Sunday Times. December 3, 2006.
-
(2006)
Sunday Times
-
-
Templeton, S.-K.1
-
65
-
-
84909599163
-
Building bridges to rare disease patients
-
September/October
-
White W. Building bridges to rare disease patients. Pharm Commerce. September/October 2012:14.
-
(2012)
Pharm Commerce
, pp. 14
-
-
White, W.1
-
67
-
-
84909579650
-
-
Toronto: Canadian Organization for Rare Disorders. Available from: Accessed 19 March 2014
-
Canadian Organization for Rare Disorders. Newsletter July 2012. Toronto: Canadian Organization for Rare Disorders. 2012. Available from: http://www.raredisorders.ca/documents/CORD-Summer2012Newsletter.v4.pdf. Accessed 19 March 2014.
-
(2012)
Newsletter July 2012
-
-
-
68
-
-
84863369347
-
Rare diseases: Canada's "research orphans"
-
Gupta S. Rare diseases: Canada's "research orphans." Open Med. 2012;6(1):e24-7.
-
(2012)
Open Med
, vol.6
, Issue.1
, pp. e24-e27
-
-
Gupta, S.1
-
69
-
-
84909625920
-
-
Toronto: Canadian Organization for Rare Disorders; Available from: Accessed 19 March 2014
-
Canadian Organization for Rare Disorders. Corporate Leaders. Toronto: Canadian Organization for Rare Disorders; 2014. Available from: http://www.raredisorders.ca/CorporateCouncil.html. Accessed 19 March 2014.
-
(2014)
Corporate Leaders
-
-
-
72
-
-
84862886261
-
The cost effectiveness of NHS physiotherapy support for occupational health (OH) services
-
Phillips CJ, Phillips R, Main CJ, et al. The cost effectiveness of NHS physiotherapy support for occupational health (OH) services. BMC Musculoskelet Disord. 2012;13:29.
-
(2012)
BMC Musculoskelet Disord
, vol.13
, pp. 29
-
-
Phillips, C.J.1
Phillips, R.2
Main, C.J.3
-
73
-
-
84897501016
-
Achieving allocative efficiency in healthcare: Nice in theory, not so NICE in practice?
-
Paulden M, McCabe C, Karnon J. Achieving allocative efficiency in healthcare: nice in theory, not so NICE in practice? Pharmacoeconomics. 2014;32(4):315-8.
-
(2014)
Pharmacoeconomics
, vol.32
, Issue.4
, pp. 315-318
-
-
Paulden, M.1
McCabe, C.2
Karnon, J.3
-
74
-
-
84897522245
-
Can the real opportunity cost stand up: Displaced services, the straw man outside the room
-
Eckermann S, Pekarsky B. Can the real opportunity cost stand up: displaced services, the straw man outside the room. Pharmacoeconomics. 2014;32(4):319-25.
-
(2014)
Pharmacoeconomics
, vol.32
, Issue.4
, pp. 319-325
-
-
Eckermann, S.1
Pekarsky, B.2
-
75
-
-
84861928513
-
Which orphans will find a home? The rule of rescue in resource allocation for rare diseases
-
Largent E, Pearson S. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012;42(1):27-34.
-
(2012)
Hastings Cent Rep
, vol.42
, Issue.1
, pp. 27-34
-
-
Largent, E.1
Pearson, S.2
-
76
-
-
55249116853
-
Public healthcare resource allocation and the rule of rescue
-
Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics. 2008;34:540-4.
-
(2008)
J Med Ethics
, vol.34
, pp. 540-544
-
-
Cookson, R.1
McCabe, C.2
Tsuchiya, A.3
-
77
-
-
84861951692
-
How should we model rare disease allocation decisions?
-
London AJ. How should we model rare disease allocation decisions? Hastings Cent Rep. 2012;42(1):3.
-
(2012)
Hastings Cent Rep
, vol.42
, Issue.1
, pp. 3
-
-
London, A.J.1
-
78
-
-
34250367132
-
OFT, VBP: QED?
-
Claxton K. OFT, VBP: QED? Health Econ. 2007;16:545-58.
-
(2007)
Health Econ
, vol.16
, pp. 545-558
-
-
Claxton, K.1
-
79
-
-
84863517632
-
Orphan drug development: An economically viable strategy for biopharma R&D
-
Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13-14):660-4.
-
(2012)
Drug Discov Today
, vol.17
, Issue.13-14
, pp. 660-664
-
-
Meekings, K.N.1
Williams, C.S.2
Arrowsmith, J.E.3
-
80
-
-
79958849417
-
Pricing and reimbursement of orphan drugs: The need for more transparency
-
Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
-
(2011)
Orphanet J Rare Dis
, vol.6
, pp. 42
-
-
Simoens, S.1
-
81
-
-
84888319689
-
Do ultra-orphan medicinal products warrant ultra-high prices? A review
-
Picavet E, Cassiman D, Simoens S. Do ultra-orphan medicinal products warrant ultra-high prices? A review. Orphan Drugs Res Rev. 2013;3:23-31.
-
(2013)
Orphan Drugs Res Rev
, vol.3
, pp. 23-31
-
-
Picavet, E.1
Cassiman, D.2
Simoens, S.3
-
82
-
-
84887541924
-
Funding innovation for treatment for rare diseases: Adopting a cost-based yardstick approach
-
Fellows GK, Hollis A. Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. Orphanet J Rare Dis. 2013;8:180.
-
(2013)
Orphanet J Rare Dis
, vol.8
, pp. 180
-
-
Fellows, G.K.1
Hollis, A.2
|